Business Context and Reporting Period
Phibro Animal Health Corporation is a global animal health, mineral nutrition and performance products company serving food-animal producers, veterinarians, feed manufacturers and distributors in more than 75 countries. The company operates through Animal Health, Mineral Nutrition and Performance Products segments.
This Form 10-K reports the fiscal year ended June 30, 2020, with comparisons to fiscal 2019 and 2018. The provided request metadata references “2019 Q4,” but the filing is an annual fiscal 2020 report. The fourth quarter ended June 30, 2020, was materially affected by COVID-19-related demand disruption.
Key Financial Metrics
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Net sales | $800.4 million | $828.0 million | Down 3% |
| Gross profit | $256.9 million | $264.6 million | Down 3% |
| Gross margin | 32.1% | 32.0% | Up 0.1 percentage points |
| Operating income | $69.2 million | $83.2 million | Down 17% |
| Net income | $33.6 million | $54.7 million | Down 39% |
| Diluted EPS | $0.83 | $1.35 | Down $0.52 |
| Adjusted EBITDA | $102.1 million | $118.0 million | Down 13% |
| Cash flow from operations | $59.3 million | $47.2 million | Up $12.2 million |
| Capital expenditures | $34.0 million | $29.9 million | Up $4.2 million |
Net income margin declined to 4.2% from 6.6%, while operating margin declined to 8.6% from 10.1%. The FY2020 effective tax rate increased to 39.6% from 23.5%, principally due to higher GILTI tax, changes in uncertain tax positions and increased foreign valuation allowances.
Segment Performance
- Animal Health: Sales of $526.9 million, down 1%; Adjusted EBITDA of $123.1 million, down 10%. MFA and other sales declined 8%, primarily because of a $30.9 million decline in China associated with African Swine Fever and regulatory changes. Nutritional specialties increased 14%, aided by the Osprey acquisition, and vaccines increased 10%.
- Mineral Nutrition: Sales of $214.4 million, down 8%, primarily because lower commodity-linked selling prices outweighed volume benefits. Adjusted EBITDA declined 7% to $14.7 million.
- Performance Products: Sales of $59.0 million, down 5%, primarily due to lower copper-based product volumes. Adjusted EBITDA was $4.5 million, down 4%.
Cash Flow, Debt and Liquidity
- Cash, cash equivalents and short-term investments totaled $91.3 million at June 30, 2020, compared with $81.6 million at June 30, 2019. Cash and cash equivalents alone were $36.3 million.
- Working capital was $222.0 million, compared with $242.9 million, and the current asset-to-current liability ratio was 2.6:1.
- Total debt was $387.0 million, consisting principally of a $218.8 million Term A loan and $169.0 million drawn on the revolving credit facility. Debt increased from $326.2 million, largely to fund the Osprey acquisition.
- The revolving facility had $78.3 million available after $2.7 million of letters of credit. The credit facilities mature in June 2022, and the company was in compliance with its financial covenants at year-end.
- Operating cash flow was $59.3 million. Investing activities used $120.4 million, including $54.5 million for Osprey, $34.0 million of capital expenditures and $31.0 million of short-term investment purchases. Financing activities provided $40.9 million, including $73.0 million of net revolver borrowings.
- The company paid $19.4 million of dividends in FY2020 and declared a $0.12-per-share dividend payable September 23, 2020. Management stated that liquidity was expected to be adequate for at least the next twelve months, subject to COVID-19 and operating-performance risks.
Material Changes Versus the Prior Comparable Period
- COVID-19 caused a short-term demand decline during the June 2020 quarter, particularly in Animal Health, while production facilities continued operating despite supply-chain and logistics challenges.
- Revenue declined $27.6 million, while SG&A increased $6.3 million because of investments in product development, strategic initiatives, the Osprey acquisition and higher corporate costs.
- Osprey Biotechnics was acquired in August 2019 for $54.5 million in cash. The acquisition added $25.3 million of goodwill and $32.4 million of definite-lived intangible assets. A $2.8 million reduction in estimated contingent consideration benefited FY2020 SG&A.
- Net income and Adjusted EBITDA declined substantially despite a slight improvement in gross margin, reflecting lower volumes and unfavorable Animal Health mix, higher operating expenses, increased interest expense and a higher tax rate.
- The company adopted the new lease accounting standard effective July 1, 2019, recognizing $18.6 million of right-of-use assets and $19.4 million of lease liabilities at adoption.
- Comprehensive income was a loss of $10.7 million, primarily because of foreign currency translation losses, derivative valuation changes and pension losses.
Guidance, Outlook, Risks and Unusual Items
- No specific numerical fiscal 2021 revenue or earnings guidance is provided in the filing. Management expects adequate liquidity for at least twelve months but cautions that COVID-19, economic conditions and covenant compliance could affect funding capacity.
- The company expects continued global livestock-health growth, supported by population growth, rising protein demand and productivity needs, but near-term results remain sensitive to pandemic-related disruptions, customer production levels, currency volatility and raw-material costs.
- Mecadox sales were $17 million in FY2020. The FDA withdrew its prior notice concerning carbadox and proposed reviewing the regulatory method for determining residues; the FDA indicated that a new withdrawal proceeding could follow. Loss of Mecadox approval would adversely affect results.
- Antibacterials and related medicated products represented approximately 40% of FY2020 net sales. Restrictions on medically important antimicrobials, antimicrobial-resistance concerns, consumer perceptions and product bans remain significant risks.
- The company faces substantial regulatory, product-liability, environmental, supply-chain, foreign-exchange, interest-rate and international operating risks. Known environmental accruals were $5.3 million, and surety bonds and letters of credit provided $12.0 million of environmental financial assurance.
- The company has material weaknesses in internal control over financial reporting involving insufficient accounting resources, transaction-processing controls, system access and segregation of duties. Management and PwC concluded that internal controls were not effective as of June 30, 2020; remediation was ongoing and the completion date was not known.
- Other unusual or non-recurring items included $0.4 million of restructuring costs, $0.5 million of acquisition-related transaction costs, $0.3 million of acquisition-related cost of goods sold, and a $2.8 million acquisition-related benefit.
Most Important Facts for Investors to Verify
- Confirm the intended period: the filing is FY2020, not a standalone FY2019 fourth-quarter filing.
- Assess whether COVID-19 demand disruption was temporary or indicates lasting reductions in livestock production and customer purchasing.
- Monitor the FDA’s carbadox/Mecadox proceedings and the potential impact of losing $17 million of annual sales.
- Evaluate debt maturities, revolver availability, covenant headroom and refinancing requirements before the June 2022 maturity.
- Review the sustainability of cash generation after acquisition spending, capital expenditures, dividends and working-capital requirements.
- Track remediation of the material weaknesses in internal controls and consider the risk of future reporting errors or delayed filings.
- Evaluate exposure to antimicrobial restrictions, African Swine Fever, customer concentration, commodity prices, foreign currencies and operations in Israel and Brazil.